PMID- 29416731
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231112
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 9
IP  - 2
DP  - 2018 Jan 5
TI  - Comparative proteomics as a tool for identifying specific alterations within 
      interferon response pathways in human glioblastoma multiforme cells.
PG  - 1785-1802
LID - 10.18632/oncotarget.22751 [doi]
AB  - An acquisition of increased sensitivity of cancer cells to viruses is a common 
      outcome of malignant progression that justifies the development of oncolytic 
      viruses as anticancer therapeutics. Studying molecular changes that underlie the 
      sensitivity to viruses would help to identify cases where oncolytic virus therapy 
      would be most effective. We quantified changes in protein abundances in two 
      glioblastoma multiforme (GBM) cell lines that differ in the ability to induce 
      resistance to vesicular stomatitis virus (VSV) infection in response to type I 
      interferon (IFN) treatment. In IFN-treated samples we observed an up-regulation 
      of protein products of some IFN-regulated genes (IRGs). In total, the proteome 
      analysis revealed up to 20% more proteins encoded by IRGs in the glioblastoma 
      cell line, which develops resistance to VSV infection after pre-treatment with 
      IFN. In both cell lines protein-protein interaction and signaling pathway 
      analyses have revealed a significant stimulation of processes related to type I 
      IFN signaling and defense responses to viruses. However, we observed a deficiency 
      in STAT2 protein in the VSV-sensitive cell line that suggests a de-regulation of 
      the JAK/STAT/IRF9 signaling. The study has shown that the up-regulation of IRG 
      proteins induced by the IFNalpha treatment of GBM cells can be detected at the 
      proteome level. Similar analyses could be applied for revealing functional 
      alterations within the antiviral mechanisms in glioblastoma samples, accompanying 
      by acquisition of sensitivity to oncolytic viruses. The approach can be useful 
      for discovering the biomarkers that predict a potential sensitivity of individual 
      glioblastoma tumors to oncolytic virus therapy.
FAU - Tarasova, Irina A
AU  - Tarasova IA
AD  - Talrose Institute for Energy Problems of Chemical Physics, Russian Academy of 
      Sciences, 119334 Moscow, Russia.
FAU - Tereshkova, Alesya V
AU  - Tereshkova AV
AD  - Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 
      Moscow, Russia.
AD  - Chumakov Institute of Poliomyelitis and Viral Encephalitides, Russian Academy of 
      Sciences, 142782 Moscow, Russia.
FAU - Lobas, Anna A
AU  - Lobas AA
AD  - Talrose Institute for Energy Problems of Chemical Physics, Russian Academy of 
      Sciences, 119334 Moscow, Russia.
AD  - Moscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.
FAU - Solovyeva, Elizaveta M
AU  - Solovyeva EM
AD  - Talrose Institute for Energy Problems of Chemical Physics, Russian Academy of 
      Sciences, 119334 Moscow, Russia.
AD  - Moscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.
FAU - Sidorenko, Alena S
AU  - Sidorenko AS
AD  - Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 
      Moscow, Russia.
FAU - Gorshkov, Vladimir
AU  - Gorshkov V
AD  - Department of Biochemistry and Molecular Biology, University of Southern Denmark, 
      5230 Odense M, Denmark.
FAU - Kjeldsen, Frank
AU  - Kjeldsen F
AD  - Department of Biochemistry and Molecular Biology, University of Southern Denmark, 
      5230 Odense M, Denmark.
FAU - Bubis, Julia A
AU  - Bubis JA
AD  - Talrose Institute for Energy Problems of Chemical Physics, Russian Academy of 
      Sciences, 119334 Moscow, Russia.
AD  - Moscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.
FAU - Ivanov, Mark V
AU  - Ivanov MV
AD  - Talrose Institute for Energy Problems of Chemical Physics, Russian Academy of 
      Sciences, 119334 Moscow, Russia.
AD  - Moscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.
FAU - Ilina, Irina Y
AU  - Ilina IY
AD  - Orekhovich Institute of Biomedical Chemistry, 119121 Moscow, Russia.
FAU - Moshkovskii, Sergei A
AU  - Moshkovskii SA
AD  - Orekhovich Institute of Biomedical Chemistry, 119121 Moscow, Russia.
AD  - Pirogov Russian National Research Medical University, 117997 Moscow, Russia.
FAU - Chumakov, Peter M
AU  - Chumakov PM
AD  - Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 
      Moscow, Russia.
AD  - Chumakov Institute of Poliomyelitis and Viral Encephalitides, Russian Academy of 
      Sciences, 142782 Moscow, Russia.
FAU - Gorshkov, Mikhail V
AU  - Gorshkov MV
AD  - Talrose Institute for Energy Problems of Chemical Physics, Russian Academy of 
      Sciences, 119334 Moscow, Russia.
AD  - Moscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.
LA  - eng
PT  - Journal Article
DEP - 20171129
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5788599
OTO - NOTNLM
OT  - JAK/STAT pathway
OT  - comparative proteomics
OT  - glioblastoma multiforme
OT  - interferon signaling alterations
OT  - oncolytic virotherapy
COIS- CONFLICTS OF INTEREST None.
EDAT- 2018/02/09 06:00
MHDA- 2018/02/09 06:01
PMCR- 2018/01/05
CRDT- 2018/02/09 06:00
PHST- 2017/06/07 00:00 [received]
PHST- 2017/10/27 00:00 [accepted]
PHST- 2018/02/09 06:00 [entrez]
PHST- 2018/02/09 06:00 [pubmed]
PHST- 2018/02/09 06:01 [medline]
PHST- 2018/01/05 00:00 [pmc-release]
AID - 22751 [pii]
AID - 10.18632/oncotarget.22751 [doi]
PST - epublish
SO  - Oncotarget. 2017 Nov 29;9(2):1785-1802. doi: 10.18632/oncotarget.22751. 
      eCollection 2018 Jan 5.